1
|
Zhou J, Gelot C, Pantelidou C, Li A, Yücel H, Davis RE, Farkkila A, Kochupurakkal B, Syed A, Shapiro GI, Tainer JA, Blagg BSJ, Ceccaldi R, D’Andrea AD. A first-in-class Polymerase Theta Inhibitor selectively targets Homologous-Recombination-Deficient Tumors. Nat Cancer 2021; 2:598-610. [PMID: 34179826 PMCID: PMC8224818 DOI: 10.1038/s43018-021-00203-x] [Citation(s) in RCA: 141] [Impact Index Per Article: 47.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Abstract
DNA polymerase theta (POLθ) is synthetic lethal with Homologous Recombination (HR) deficiency and thus a candidate target for HR-deficient cancers. Through high-throughput small molecule screens we identified the antibiotic Novobiocin (NVB) as a specific POLθ inhibitor that selectively kills HR-deficient tumor cells in vitro and in vivo. NVB directly binds to the POLθ ATPase domain, inhibits its ATPase activity, and phenocopies POLθ depletion. NVB kills HR-deficient breast and ovarian tumors in GEMM, xenograft and PDX models. Increased POLθ levels predict NVB sensitivity, and BRCA-deficient tumor cells with acquired resistance to PARP inhibitors (PARPi) are sensitive to NVB in vitro and in vivo. Mechanistically, NVB-mediated cell death in PARPi-resistant cells arises from increased double-strand break end resection, leading to accumulation of single-strand DNA intermediates and non-functional RAD51 foci. Our results demonstrate that NVB may be useful alone or in combination with PARPi in treating HR-deficient tumors, including those with acquired PARPi resistance. (151/150).
Collapse
Affiliation(s)
- Jia Zhou
- Department of Radiation Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02215, USA
| | - Camille Gelot
- Inserm U830, PSL Research University, Institut Curie, 75005, Paris, France
| | - Constantia Pantelidou
- Department of Medical Oncology, Dana-Farber Cancer Institute and Department of Medicine, Harvard Medical School, Boston, Massachusetts, USA
| | - Adam Li
- Department of Radiation Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02215, USA
| | - Hatice Yücel
- Inserm U830, PSL Research University, Institut Curie, 75005, Paris, France
| | - Rachel E. Davis
- Department of Chemistry and Biochemistry, University of Notre Dame, Notre Dame, IN 46556, USA
| | - Anniina Farkkila
- Department of Radiation Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02215, USA
| | - Bose Kochupurakkal
- Department of Radiation Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02215, USA
| | - Aleem Syed
- Departments of Cancer Biology and of Molecular and Cellular Oncology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
| | - Geoffrey I. Shapiro
- Department of Medical Oncology, Dana-Farber Cancer Institute and Department of Medicine, Harvard Medical School, Boston, Massachusetts, USA.,Center for DNA Damage and Repair, Dana-Farber Cancer Institute, Boston, MA, USA
| | - John A. Tainer
- Departments of Cancer Biology and of Molecular and Cellular Oncology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
| | - Brian S. J. Blagg
- Department of Chemistry and Biochemistry, University of Notre Dame, Notre Dame, IN 46556, USA
| | - Raphael Ceccaldi
- Inserm U830, PSL Research University, Institut Curie, 75005, Paris, France.,Corresponding authors: Alan D. D’Andrea, M.D., Director, Susan F. Smith Center for Women’s Cancers (SFSCWC), Director, Center for DNA Damage and Repair, Dana-Farber Cancer Institute, The Fuller-American Cancer Society Professor, Harvard Medical School, Phone: 617-632-2080, , Raphael Ceccaldi, Institut Curie, 75005, Paris, France, Phone: +33 (0)1 56 24 69 49,
| | - Alan D. D’Andrea
- Department of Radiation Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02215, USA.,Center for DNA Damage and Repair, Dana-Farber Cancer Institute, Boston, MA, USA.,Susan F. Smith Center for Women’s Cancers, Dana-Farber Cancer Institute, Boston, MA, USA.,Corresponding authors: Alan D. D’Andrea, M.D., Director, Susan F. Smith Center for Women’s Cancers (SFSCWC), Director, Center for DNA Damage and Repair, Dana-Farber Cancer Institute, The Fuller-American Cancer Society Professor, Harvard Medical School, Phone: 617-632-2080, , Raphael Ceccaldi, Institut Curie, 75005, Paris, France, Phone: +33 (0)1 56 24 69 49,
| |
Collapse
|
2
|
Iyer S, Zhang S, Yucel S, Horn H, Smith SG, Reinhardt F, Hoefsmit E, Assatova B, Casado J, Meinsohn MC, Barrasa MI, Bell GW, Pérez-Villatoro F, Huhtinen K, Hynninen J, Oikkonen J, Galhenage PM, Pathania S, Hammond PT, Neel BG, Farkkila A, Pépin D, Weinberg RA. Genetically Defined Syngeneic Mouse Models of Ovarian Cancer as Tools for the Discovery of Combination Immunotherapy. Cancer Discov 2020; 11:384-407. [PMID: 33158843 DOI: 10.1158/2159-8290.cd-20-0818] [Citation(s) in RCA: 57] [Impact Index Per Article: 14.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/11/2020] [Revised: 09/08/2020] [Accepted: 11/03/2020] [Indexed: 12/12/2022]
Abstract
Despite advances in immuno-oncology, the relationship between tumor genotypes and response to immunotherapy remains poorly understood, particularly in high-grade serous tubo-ovarian carcinomas (HGSC). We developed a series of mouse models that carry genotypes of human HGSCs and grow in syngeneic immunocompetent hosts to address this gap. We transformed murine-fallopian tube epithelial cells to phenocopy homologous recombination-deficient tumors through a combined loss of Trp53, Brca1, Pten, and Nf1 and overexpression of Myc and Trp53 R172H, which was contrasted with an identical model carrying wild-type Brca1. For homologous recombination-proficient tumors, we constructed genotypes combining loss of Trp53 and overexpression of Ccne1, Akt2, and Trp53 R172H, and driven by KRAS G12V or Brd4 or Smarca4 overexpression. These lines form tumors recapitulating human disease, including genotype-driven responses to treatment, and enabled us to identify follistatin as a driver of resistance to checkpoint inhibitors. These data provide proof of concept that our models can identify new immunotherapy targets in HGSC. SIGNIFICANCE: We engineered a panel of murine fallopian tube epithelial cells bearing mutations typical of HGSC and capable of forming tumors in syngeneic immunocompetent hosts. These models recapitulate tumor microenvironments and drug responses characteristic of human disease. In a Ccne1-overexpressing model, immune-checkpoint resistance was driven by follistatin.This article is highlighted in the In This Issue feature, p. 211.
Collapse
Affiliation(s)
- Sonia Iyer
- Whitehead Institute for Biomedical Research, Cambridge, Massachusetts
| | - Shuang Zhang
- Laura and Isaac Perlmutter Cancer Center, NYU-Langone Medical Center, New York, New York
| | - Simge Yucel
- Whitehead Institute for Biomedical Research, Cambridge, Massachusetts
| | - Heiko Horn
- Stanley Center, Broad Institute of MIT and Harvard, Cambridge, Massachusetts.,Pediatric Surgical Research Laboratories, Massachusetts General Hospital; Department of Surgery, Harvard Medical School, Boston, Massachusetts
| | - Sean G Smith
- Marble Center for Cancer Nanomedicine, Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, Massachusetts
| | - Ferenc Reinhardt
- Whitehead Institute for Biomedical Research, Cambridge, Massachusetts
| | - Esmee Hoefsmit
- Whitehead Institute for Biomedical Research, Cambridge, Massachusetts
| | | | - Julia Casado
- Research Program in Systems Oncology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland
| | - Marie-Charlotte Meinsohn
- Pediatric Surgical Research Laboratories, Massachusetts General Hospital; Department of Surgery, Harvard Medical School, Boston, Massachusetts
| | | | - George W Bell
- Whitehead Institute for Biomedical Research, Cambridge, Massachusetts
| | - Fernando Pérez-Villatoro
- Research Program in Systems Oncology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland
| | - Kaisa Huhtinen
- Institute of Biomedicine and FICAN West Cancer Centre, University of Turku, Turku, Finland
| | - Johanna Hynninen
- Department of Obstetrics and Gynecology, University of Turku and Turku University Hospital, Turku, Finland
| | - Jaana Oikkonen
- Research Program in Systems Oncology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland
| | - Pamoda M Galhenage
- Center for Personalized Cancer Therapy, University of Massachusetts, Boston, Massachusetts
| | - Shailja Pathania
- Center for Personalized Cancer Therapy, University of Massachusetts, Boston, Massachusetts
| | - Paula T Hammond
- Marble Center for Cancer Nanomedicine, Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, Massachusetts
| | - Benjamin G Neel
- Laura and Isaac Perlmutter Cancer Center, NYU-Langone Medical Center, New York, New York
| | - Anniina Farkkila
- Research Program in Systems Oncology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.,Dana-Farber Cancer Institute Harvard Medical School, Boston, Massachusetts
| | - David Pépin
- Pediatric Surgical Research Laboratories, Massachusetts General Hospital; Department of Surgery, Harvard Medical School, Boston, Massachusetts.
| | - Robert A Weinberg
- Whitehead Institute for Biomedical Research, Cambridge, Massachusetts. .,Department of Biology, Massachusetts Institute of Technology, Cambridge, Massachusetts.,Massachusetts Institute of Technology Ludwig Center for Molecular Oncology, Cambridge, Massachusetts
| |
Collapse
|
3
|
Iyer S, Zhang S, Farkkila A, Smith S, Pepin D, Mohan R, Xia T, Reinhardt F, Chavarria T, Hoefsmit E, Poort V, Pathania S, Zhou Y, Elias KM, Hammond PT, Neel BG, Weinberg RA. Abstract B61: The genotype of serous carcinomas shapes the tumor microenvironment and modulates responses to targeted and immune checkpoint therapies. Clin Cancer Res 2020. [DOI: 10.1158/1557-3265.ovca19-b61] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Immunotherapy in ovarian cancer has been disappointing, with only ~10% of patients responding to checkpoint blockade. The determinants of this low response rate remain poorly understood and there is a pressing need for immune-competent preclinical models to elucidate the biology of immune evasion in ovarian cancer. One critical area of interest is the role of homologous recombination (HR) DNA repair in immune evasion. The types and abundance of potential antigens present on cancer cells may depend on the genotype of the tumor, its mutational burden, and the cellular state. Unfortunately, the preclinical tools required to explore the relationship between the types of DNA damage repair deficiencies and immune evasion have been lacking. To this end, we have engineered novel syngeneic mouse models from murine fallopian tube epithelium using CRISPR/Cas9 technology. These tumors capture the most common combinations of co-occurring mutations observed in homologous recombination-deficient and -proficient patient samples. These models can identify the contribution of common driver mutations, which are TP53, BRCA1, PTEN, MYC, Cyclin E1 (CCNE1), AKT2, and Kras, to the heterotypic interactions between cancer and stromal/immune compartments and examine how DNA repair proficiency contributes to immunogenicity. To validate the DNA repair proficiency of the transformed cells, we measured Rad51 nuclear focus formation after ionizing radiation (IR) and PARP inhibitor and DNA-damaging agent sensitivity. The HR-deficient cell lines had significantly fewer Rad51 nuclear foci and were more sensitive to PARP inhibition in comparison to HR-proficient cells. Initial immune/stromal analysis using flow cytometry, single-cell RNASeq (scRNASeq) transcriptomic, and immunofluorescence imaging analysis revealed substantial differences in the myeloid and T-cell regulatory compartments between HR-proficient and -deficient primary and metastatic tumors and within the ascitic fluid. Preliminary results also suggest that inhibition of the DNA damage response (DDR), checkpoint kinase 1 (Chk1) in combination with immune checkpoint inhibitors, potentiates antitumor effects and augments cytotoxic T-cell infiltration. In conclusion, these results reveal how common mutational drivers, and particularly those associated with HR status, determine the microenvironment of the tumor and its response to treatment. Understanding the genetic basis of these complex cellular interactions will be critical to better tailor combinations of existing targeted treatments and immunotherapies in ovarian cancer to fight this devastating disease.
Citation Format: Sonia Iyer, Shuang Zhang, Anniina Farkkila, Sean Smith, David Pepin, Raghav Mohan, Tian Xia, Ferenc Reinhardt, Tony Chavarria, Esmee Hoefsmit, Vera Poort, Shailja Pathania, Yunlan Zhou, Kevin M. Elias, Paula T. Hammond, Benjamin G. Neel, Robert A. Weinberg. The genotype of serous carcinomas shapes the tumor microenvironment and modulates responses to targeted and immune checkpoint therapies [abstract]. In: Proceedings of the AACR Special Conference on Advances in Ovarian Cancer Research; 2019 Sep 13-16, 2019; Atlanta, GA. Philadelphia (PA): AACR; Clin Cancer Res 2020;26(13_Suppl):Abstract nr B61.
Collapse
Affiliation(s)
- Sonia Iyer
- 1Whitehead Institute for Biomedical Research, Cambridge, MA,
| | | | | | - Sean Smith
- 4Massachusetts Institute of Technology, Boston, MA,
| | - David Pepin
- 5Massachusetts General Hospital, Boston, USA,
| | | | - Tian Xia
- 1Whitehead Institute for Biomedical Research, Cambridge, MA,
| | | | - Tony Chavarria
- 1Whitehead Institute for Biomedical Research, Cambridge, MA,
| | - Esmee Hoefsmit
- 1Whitehead Institute for Biomedical Research, Cambridge, MA,
| | - Vera Poort
- 1Whitehead Institute for Biomedical Research, Cambridge, MA,
| | | | | | | | | | | | | |
Collapse
|
4
|
Iyer S, Zhang S, Farkkila A, Smith SG, Pepin D, Mohan R, Hoefsmit E, Xia T, Reinhardt F, Chavarria TE, Pathania S, Zhou Y, Elias KM, Neel BG, Weinberg RA. Abstract A29: The genomic architecture of serous carcinomas shapes the tumor microenvironment and modulates responses to targeted and immunotherapies. Cancer Immunol Res 2020. [DOI: 10.1158/2326-6074.tumimm19-a29] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Immunotherapy in ovarian cancer has been disappointing, with only ~10% of patients responding to checkpoint blockade. The determinants of this low response rate remain poorly understood, and there is a pressing need for immune-competent preclinical models to elucidate the biology of immune evasion in ovarian cancer. One critical area of interest is the role of homologous recombination (HR) repair in immune evasion. The types and abundance of potential antigens present on cancer cells may depend on the genotype of the tumor, its mutational burden, and the cellular state. Unfortunately, the preclinical tools required to explore the relationship between the types of DNA damage repair deficiencies and immune evasion have been lacking. To this end, we have engineered novel syngeneic mouse models from murine fallopian tube epithelium using CRISPR/Cas9 technology. These tumors capture the most common combinations of co-occurring mutations observed in homologous recombination-deficient and -proficient patient samples. These models can identify the contribution of common driver mutations, which are TP53, BRCA1, PTEN, Myc, Cyclin E1 (CCNE1), Akt2, and Kras, to the heterotypic interactions between cancer and stromal/immune compartments and examine how DNA repair proficiency contributes to immunogenicity. To validate the DNA repair proficiency of the transformed cells, we measured Rad51 nuclear focus formation after ionizing radiation (IR) and PARP inhibitor and DNA-damaging agent sensitivity. The HR-deficient cell lines had significantly fewer Rad51 nuclear foci and were more sensitive to PARP inhibition in comparison to HR-proficient cells. Initial immune/stromal analysis using flow cytometry, single-cell RNA sequencing, and transcriptomic and immunofluorescence analysis revealed substantial differences in the myeloid and regulatory compartments between HR-proficient and -deficient tumors within the primary and metastatic tumors themselves and within the ascitic fluid. Preliminary results also suggest that inhibition of the DNA damage response (DDR), checkpoint kinase 1 (Chk1) in combination with immune checkpoint inhibitors, potentiates antitumor effects and augments cytotoxic T-cell infiltration. In conclusion, these results reveal how common mutational drivers, and particularly those associated with HR status, determine the microenvironment of the tumor and its response to treatment. Understanding the genetic basis of these complex cellular interactions will be critical to better tailor combinations of existing targeted treatments and immunotherapies in ovarian cancer to fight this devastating disease.
Citation Format: Sonia Iyer, Shuang Zhang, Anniina Farkkila, Sean G. Smith, David Pepin, Raghav Mohan, Esmee Hoefsmit, Tian Xia, Ferenc Reinhardt, Tony E. Chavarria, Shailja Pathania, Yunlan Zhou, Kevin M. Elias, Benjamin G. Neel, Robert A. Weinberg. The genomic architecture of serous carcinomas shapes the tumor microenvironment and modulates responses to targeted and immunotherapies [abstract]. In: Proceedings of the AACR Special Conference on Tumor Immunology and Immunotherapy; 2019 Nov 17-20; Boston, MA. Philadelphia (PA): AACR; Cancer Immunol Res 2020;8(3 Suppl):Abstract nr A29.
Collapse
Affiliation(s)
- Sonia Iyer
- 1Whitehead Institute for Biomedical Research, Cambridge, MA,
| | | | | | - Sean G. Smith
- 4Massachusetts Institute of Technology, Cambridge, MA,
| | - David Pepin
- 5Massachusetts General Hospital, Boston, MA,
| | | | - Esmee Hoefsmit
- 1Whitehead Institute for Biomedical Research, Cambridge, MA,
| | - Tian Xia
- 1Whitehead Institute for Biomedical Research, Cambridge, MA,
| | | | | | | | | | | | | | | |
Collapse
|
5
|
Iyer S, Zhang S, Farkkila A, Smith S, Pepin D, Mohan R, Reinhardt F, Xia T, Chavarria TE, Hoefsmit E, Pathania S, Zhou Y, Elias KM, Neel BG, Weinberg RA. Abstract PR04: The genomic architecture of serous carcinomas shapes the tumor microenvironment and modulates responses to targeted and immunotherapies. Mol Cancer Ther 2019. [DOI: 10.1158/1535-7163.targ-19-pr04] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
High-grade serous ovarian cancer (HGSOC) is the most frequent and most aggressive histologic subtype of ovarian cancer. The cornerstone of the existing treatment of HGSOC is DNA-damaging chemotherapy; however, practically all patients eventually develop a progressive disease and the 5-year survival is only 40%. Immunotherapy would seem to be an attractive alternative treatment to chemotherapy, yet existing immunotherapies perform poorly in ovarian cancer, with only ~10% of patients responding to checkpoint blockade. Why this is the case remains poorly understood and there is a pressing need to understand the underlying biology of immune evasion in ovarian cancer. One critical area of interest is the role of homology-dependent DNA repair (HR) in immune evasion. The types and abundance of potential antigens present on cancer cells may depend on the genotype of the tumor, its mutational burden, and the cellular state. Unfortunately, the preclinical tools required to explore the relationship between the types of DNA damage repair deficiencies and immune evasion have been lacking. Hence, we have modeled the biology of ovarian cancer using patient-relevant mutational landscapes in an immune-proficient, syngeneic mouse model in order to help us identify the contribution of common driver mutations to the immune repertoire in the tumor microenvironment, and thus to responses of HGSOC tumors to immunotherapy. We hypothesize that the immune composition and gene expression signatures of the resulting tumors will vary based on the combination of genetic alterations and the DNA repair proficiency of the transformed cells. To this end, we have engineered novel syngeneic mouse models from murine fallopian tube epithelium using CRISPR/Cas9 technology. These tumors capture the most common combinations of co-occurring mutations observed in HR-deficient and -proficient patient samples. These models can identify the contribution of common driver mutations which are TP53, BRCA1, PTEN, MYC, Cyclin E1 (CCNE1), AKT2, and Kras to the heterotypic interactions between cancer and stromal/immune compartments and examine how DNA repair proficiency contributes to immunogenicity. To validate the DNA repair proficiency of the transformed cells, we measured Rad51 nuclear focus formation after ionizing radiation (IR) and PARP inhibitor and DNA-damaging agent sensitivity. The HR-deficient cell lines had significantly fewer Rad51 nuclear foci and were more sensitive to PARP inhibition in comparison to HR-proficient cells. Initial immune /stromal analysis using flow cytometry, scRNAseq transcriptomic and immunofluorescence analysis revealed substantial differences in the myeloid and T-cell regulatory compartments between HR-proficient and -deficient primary and metastatic tumors and within the ascitic fluid. Preliminary results also suggest that inhibition of the DNA damage response (DDR), checkpoint kinase 1 (Chk1) in combination with immune checkpoint inhibitors, potentiates antitumor effects and augments cytotoxic T-cell infiltration. In conclusion, these results reveal how common mutational drivers, and particularly those associated with HR status, determine the microenvironment of the tumor and its response to treatment. Understanding the genetic basis of these complex cellular interactions will be critical to better tailor combinations of existing targeted treatments and immunotherapies in ovarian cancer to fight this devastating disease.
Citation Format: Sonia Iyer, Shuang Zhang, Anniina Farkkila, Sean Smith, David Pepin, Raghav Mohan, Ferenc Reinhardt, Tian Xia, Tony E. Chavarria, Esmee Hoefsmit, Shailja Pathania, Yunlan Zhou, Kevin M. Elias, Benjamin G. Neel, Robert A. Weinberg. The genomic architecture of serous carcinomas shapes the tumor microenvironment and modulates responses to targeted and immunotherapies [abstract]. In: Proceedings of the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics; 2019 Oct 26-30; Boston, MA. Philadelphia (PA): AACR; Mol Cancer Ther 2019;18(12 Suppl):Abstract nr PR04. doi:10.1158/1535-7163.TARG-19-PR04
Collapse
Affiliation(s)
- Sonia Iyer
- 1Whitehead Institute for Biomedical Research, Cambridge, MA
| | | | | | - Sean Smith
- 4Massachusetts Institute of Technology, Cambridge, MA
| | | | | | | | - Tian Xia
- 1Whitehead Institute for Biomedical Research, Cambridge, MA
| | | | - Esmee Hoefsmit
- 1Whitehead Institute for Biomedical Research, Cambridge, MA
| | | | | | | | | | | |
Collapse
|
6
|
Parmar K, Kochupurakkal BS, Lazaro JB, Wang ZC, Palakurthi S, Kirschmeier PT, Yang C, Sambel LA, Farkkila A, Reznichenko E, Reavis HD, Dunn CE, Zou L, Do KT, Konstantinopoulos PA, Matulonis UA, Liu JF, D’Andrea AD, Shapiro GI. The CHK1 Inhibitor Prexasertib Exhibits Monotherapy Activity in High-Grade Serous Ovarian Cancer Models and Sensitizes to PARP Inhibition. Clin Cancer Res 2019; 25:6127-6140. [PMID: 31409614 PMCID: PMC6801076 DOI: 10.1158/1078-0432.ccr-19-0448] [Citation(s) in RCA: 90] [Impact Index Per Article: 18.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/04/2019] [Revised: 04/24/2019] [Accepted: 07/16/2019] [Indexed: 12/15/2022]
Abstract
PURPOSE PARP inhibitors are approved for the treatment of high-grade serous ovarian cancers (HGSOC). Therapeutic resistance, resulting from restoration of homologous recombination (HR) repair or replication fork stabilization, is a pressing clinical problem. We assessed the activity of prexasertib, a checkpoint kinase 1 (CHK1) inhibitor known to cause replication catastrophe, as monotherapy and in combination with the PARP inhibitor olaparib in preclinical models of HGSOC, including those with acquired PARP inhibitor resistance. EXPERIMENTAL DESIGN Prexasertib was tested as a single agent or in combination with olaparib in 14 clinically annotated and molecularly characterized luciferized HGSOC patient-derived xenograft (PDX) models and in a panel of ovarian cancer cell lines. The ability of prexasertib to impair HR repair and replication fork stability was also assessed. RESULTS Prexasertib monotherapy demonstrated antitumor activity across the 14 PDX models. Thirteen models were resistant to olaparib monotherapy, including 4 carrying BRCA1 mutation. The combination of olaparib with prexasertib was synergistic and produced significant tumor growth inhibition in an olaparib-resistant model and further augmented the degree and durability of response in the olaparib-sensitive model. HGSOC cell lines, including those with acquired PARP inhibitor resistance, were also sensitive to prexasertib, associated with induction of DNA damage and replication stress. Prexasertib also sensitized these cell lines to PARP inhibition and compromised both HR repair and replication fork stability. CONCLUSIONS Prexasertib exhibits monotherapy activity in PARP inhibitor-resistant HGSOC PDX and cell line models, reverses restored HR and replication fork stability, and synergizes with PARP inhibition.
Collapse
Affiliation(s)
- Kalindi Parmar
- Center for DNA Damage and Repair, Dana-Farber Cancer Institute, Boston, Massachusetts,Department of Radiation Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts
| | - Bose S. Kochupurakkal
- Center for DNA Damage and Repair, Dana-Farber Cancer Institute, Boston, Massachusetts,Department of Radiation Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts
| | - Jean-Bernard Lazaro
- Center for DNA Damage and Repair, Dana-Farber Cancer Institute, Boston, Massachusetts,Department of Radiation Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts
| | - Zhigang C. Wang
- Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts
| | - Sangeetha Palakurthi
- Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, Massachusetts
| | - Paul T. Kirschmeier
- Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, Massachusetts
| | - Chunyu Yang
- Center for DNA Damage and Repair, Dana-Farber Cancer Institute, Boston, Massachusetts,Department of Radiation Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts
| | - Larissa A. Sambel
- Center for DNA Damage and Repair, Dana-Farber Cancer Institute, Boston, Massachusetts,Department of Radiation Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts
| | - Anniina Farkkila
- Center for DNA Damage and Repair, Dana-Farber Cancer Institute, Boston, Massachusetts,Department of Radiation Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts
| | - Elizaveta Reznichenko
- Center for DNA Damage and Repair, Dana-Farber Cancer Institute, Boston, Massachusetts,Department of Radiation Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts
| | - Hunter D Reavis
- Center for DNA Damage and Repair, Dana-Farber Cancer Institute, Boston, Massachusetts,Department of Radiation Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts
| | - Connor E. Dunn
- Center for DNA Damage and Repair, Dana-Farber Cancer Institute, Boston, Massachusetts,Department of Radiation Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts
| | - Lee Zou
- Department of Pathology, Massachusetts General Hospital Cancer Center and Harvard Medical School, Charlestown, Massachusetts
| | - Khanh T. Do
- Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts,Department of Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, Massachusetts
| | - Panagiotis A. Konstantinopoulos
- Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts,Department of Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, Massachusetts
| | - Ursula A. Matulonis
- Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts,Department of Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, Massachusetts
| | - Joyce F. Liu
- Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts,Department of Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, Massachusetts
| | - Alan D. D’Andrea
- Center for DNA Damage and Repair, Dana-Farber Cancer Institute, Boston, Massachusetts,Department of Radiation Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts
| | - Geoffrey I. Shapiro
- Center for DNA Damage and Repair, Dana-Farber Cancer Institute, Boston, Massachusetts,Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts,Department of Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, Massachusetts
| |
Collapse
|
7
|
Konstantinopoulos P, Wahner Hendrickson A, Penson R, Doyle A, Kohn E, Duska L, Crispens M, Olawaiye A, Winer I, Barroilhet L, Fu S, McHale M, Schilder R, Farkkila A, Curtis J, Quinn R, Whalen C, Shapiro G, Matulonis U. Randomized phase II (RP2) study of ATR inhibitor M6620 in combination with gemcitabine versus gemcitabine alone in platinum-resistant high grade serous ovarian cancer (HGSOC). Ann Oncol 2019. [DOI: 10.1093/annonc/mdz394.057] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
8
|
Farkkila A, Chopra SS, Lin JR, Maliga Z, Koruchupakkal B, Strickland KC, Howitt BE, Santagata S, Matulonis UA, Elias K, Swisher EM, Konstantinopoulos PA, Sorger P, D'Andrea AD. Abstract 139: DNA damage and immunoprofiling with highly multiplexed tissue immunofluorescence (t-CycIF) in high-grade serous ovarian cancer. Cancer Res 2018. [DOI: 10.1158/1538-7445.am2018-139] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Immune checkpoint blockade (ICB) has emerged as a new promising therapeutic approach in multiple cancers, however, the responses to single-agent ICBs have been modest in high-grade serous ovarian cancer (HGSOC). Preclinical- and early clinical data show promising efficacy of combining DNA damaging agents with immunotherapy. An improved understanding of the interplay between DNA damage in cancer cells and anti-tumor immune responses may therefore accelerate the development of rational drug combinations and identify predictive biomarkers. The majority of HGSOC are deficient in homologous recombination (HR) DNA repair, and use alternative, error-prone DNA repair pathways, that have been shown to be associated with increased immune recognition (Strickland et al, 2016). Compelling evidence has shown that DNA damaging agents increase the expression of immune-regulatory genes, such as MCH class I antigens, and interferons in HR deficient tumors. Further, HR deficient tumor exhibit an increased response to ICBs, and DNA damage-driven activation of interferon signalling has been shown to overcome resistance to ICBs (Wang et al, 2016). To reveal the relationship between intrinsic and treatment-induced DNA damage and the HGSOC immune microenvironment we are employing a novel, high-multiplex tissue cyclic immunofluorescence (t-CycIF) platform (Lin et al, 2016& 2017) allowing for the simultaneous detection of up to 60 different antigens at single cell resolution. Utilizing t-CycIF we are in the process of profiling the DNA damage and immune responses in three unique HGSOC clinical cohorts including i) tumors with inherent DNA repair deficiencies ii) pre- and post DNA damaging therapy iii) tumors collected in an innovative clinical trial combining Poly- ADP Ribose Polymerase inhibitor (PARPi) Niraparib and ICB Pembrolizumab. Using this high-dimensional, quantitative data we are mapping the abundance, spatial arrangement and functional state of cancer cells, immune cells, and stroma in the HGSOC microenvironment. The highly multiplexed t-CycIF data are processed with established computational algorithms and correlated with clinical outcomes. Our preliminary data shows that t-CycIF sensitively captures immune cell subpopulations, tumor heterogeneity and DNA damage in HGSOC. We anticipate that t-CycIF could accelerate the development of rational strategies for combining DNA damaging agents with immunotherapy to ultimately improve the treatment and outcomes of patients with ovarian cancer.
Citation Format: Anniina Farkkila, Sameer S. Chopra, Jia-Ren Lin, Zoltan Maliga, Bose Koruchupakkal, Kyle C. Strickland, Brooke E. Howitt, Sandro Santagata, Ursula A. Matulonis, Kevin Elias, Elizabeth M. Swisher, Panagiotis A. Konstantinopoulos, Peter Sorger, Alan D. D'Andrea. DNA damage and immunoprofiling with highly multiplexed tissue immunofluorescence (t-CycIF) in high-grade serous ovarian cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2018; 2018 Apr 14-18; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2018;78(13 Suppl):Abstract nr 139.
Collapse
Affiliation(s)
- Anniina Farkkila
- 1Dana Farber Cancer Institute, Brigham and Women's Hospital, Harvard Medical School, Boston, MA
| | | | | | | | - Bose Koruchupakkal
- 1Dana Farber Cancer Institute, Brigham and Women's Hospital, Harvard Medical School, Boston, MA
| | - Kyle C. Strickland
- 1Dana Farber Cancer Institute, Brigham and Women's Hospital, Harvard Medical School, Boston, MA
| | - Brooke E. Howitt
- 1Dana Farber Cancer Institute, Brigham and Women's Hospital, Harvard Medical School, Boston, MA
| | - Sandro Santagata
- 3Harvard Medical School, Brigham and Women's Hospital, Boston, MA
| | - Ursula A. Matulonis
- 1Dana Farber Cancer Institute, Brigham and Women's Hospital, Harvard Medical School, Boston, MA
| | - Kevin Elias
- 4Brigham and Women's Hospital, Harvard Medical School, Boston, MA
| | | | | | | | - Alan D. D'Andrea
- 1Dana Farber Cancer Institute, Brigham and Women's Hospital, Harvard Medical School, Boston, MA
| |
Collapse
|
9
|
Farkkila A, Zhang K, Kaipio K, Lamminen T, Lehtonen R, Hynninen J, Grénman S, Carpén O, Hautaniemi S, Vähärautio A. Abstract 1428: Single-cell transcriptomics reveals differential DNA repair signatures after chemotherapy in high-grade serous ovarian cancer. Cancer Res 2017. [DOI: 10.1158/1538-7445.am2017-1428] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Resistance to chemotherapy poses a major clinical problem in the treatment of ovarian cancer. The efficacy of platinum- based chemotherapy relies on defective DNA repair mechanisms, and increased expression of homologous recombination (HR)/DNA repair genes in primary tumor samples is associated with improved chemoresponse. However, the effects of neo-adjuvant chemotherapy (NACT) on the expression DNA repair genes in cancer cells are poorly understood. In addition, high-grade serous ovarian cancers (HGSOCs) display significant inter- and intratumoral heterogeneity, and the identification of mechanisms of drug resistance has been hampered by the lack of data at the single cell resolution.
We collected 34 primary and 20 interval tumor samples from 15 patients treated for HGSOC at the Turku University Hospital, Finland. Tumor tissue total RNA was sequenced with Illumina HiSeq. For this study, we selected 363 genes selected due to their validated role in DNA repair pathways and compared their expression profiles between primary and interval samples. The treatment naïve primary tumor samples highly expressed genes related to HR, such as BRCA2, RAD54, PARPBP, FANCD2, and POLQ. Whereas after NACT the interval samples highly expressed genes regulating cell cycle, inflammatory response, and the drug efflux pump ABCB1. Moreover, higher expression of BRCA2 or POLQ in the interval samples correlated with poor primary therapy outcome (p<0.01).
To reveal the transcriptomics landscapes of treatment naïve and NACT treated HGSOCs at the single cell level, we performed single cell mRNA sequencing of primary and interval samples using the Fluidigm C1 Platform. Unsupervised clustering revealed eight distinct cell subpopulations, of which two clusters were annotated HGSOC cells based on enriched expression of cancer specific genes. In global gene expression analysis of 98 HGSOC cells, the most differentially expressed genes in primary HGSOC cells were heat shock proteins reflecting active protein synthesis. By contrast, the cancer cells from interval samples highly expressed genes regulating the cell cycle and immune response. Of the DNA repair pathway genes, the interval samples expressed lower levels of HES1, a transcription factor that is known to promote cancer progression and stemness.
The herein elucidated DNA repair pathway transcriptomics landscape at single-cell and whole tumor level provides novel targets for overcoming chemoresistance in HGSOC.
Citation Format: Anniina Farkkila, Kaiyang Zhang, Katja Kaipio, Tarja Lamminen, Rainer Lehtonen, Johanna Hynninen, Seija Grénman, Olli Carpén, Sampsa Hautaniemi, Anna Vähärautio. Single-cell transcriptomics reveals differential DNA repair signatures after chemotherapy in high-grade serous ovarian cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2017; 2017 Apr 1-5; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2017;77(13 Suppl):Abstract nr 1428. doi:10.1158/1538-7445.AM2017-1428
Collapse
Affiliation(s)
- Anniina Farkkila
- 1Univ. of Helsinki and Helsinki University Hospital, Helsinki, Finland
| | | | | | | | | | - Johanna Hynninen
- 4University of Turku and Turku University Hospital, Turku, Finland
| | - Seija Grénman
- 4University of Turku and Turku University Hospital, Turku, Finland
| | - Olli Carpén
- 1Univ. of Helsinki and Helsinki University Hospital, Helsinki, Finland
| | | | | |
Collapse
|
10
|
McConechy MK, Farkkila A, Yang W, Andersson N, Ng Y, Unkila-Kallio L, McAlpine JN, Gilks B, Anttonen M, Huntsman DG. Abstract 5610: Circulating tumor DNA: FOXL2 402C-G mutation can be identified in plasma from adult granulosa cell tumor patients with recurrent disease. Cancer Res 2014. [DOI: 10.1158/1538-7445.am2014-5610] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Adult granulosa cell tumors (aGCT) represent 2-5% of all ovarian cancers. Most patients present with stage 1 disease and have a good prognosis, however up to 30% of aGCTs will recur (median=7 years), and 50% of these patients die of aGCT. These women require prolonged surveillance for serum tumor markers. In recent years, the detection of somatic mutations in free circulating tumor DNA (ctDNA) in plasma has been investigated as a non-invasive method to diagnose and monitor different cancers. The analysis of plasma DNA, which is a mixture of ctDNA and normal DNA, can be extended to aGCT patients that are at risk to recur, which would involve testing for the presence of the FOXL2 402C->G mutation. This mutation is known to be present in 95% of aGCTs; FOXL2 mutation testing is currently being used to aid in tumor differential diagnosis.
FOXL2 mutations in free ctDNA can be detected in the plasma of aGCT patients and may aid in diagnosis and monitoring of patients.
Plasma samples (1-2mL) were extracted for ctDNA using the Qiagen circulating nucleic acid kit. The ctDNA was preamplified for 10 cycles using the C134W FOXL2 Taqman primer/probe, ABI genotyping mix, followed by a 1:5 dilution. Preamplified ctDNA products were subjected to droplet formation and counted on the Raindance Raindrop digital PCR instruments to detect wild type or mutant alleles. All analysis was performed using the Raindrop Analyst V2 software.
Of two aGCT cases tested, both showed detectable plasma ctDNA FOXL2 mutations using Raindance Raindrop digital PCR. For case 1, plasma from two subsequent time points were tested. The FOXL2 mutation was not detected in the first time point, 12 years from diagnosis, at which time the patient had relapsed disease and underwent chemotherapy. Surgery for extensive tumor burden was performed at the second time point, 6 months later, and a 16% allelic frequency of the FOXL2 mutation was detected in the plasma DNA. For case 2, two plasma samples were tested, the first from the primary surgery, the second at relapse two years later. The FOXL2 ctDNA mutation was present at 6% in the recurrent plasma sample, but not at primary diagnosis. The recurrence was originally diagnosed as a high-grade serous ovarian carcinoma, however the tumor was FOXL2 mutation positive and later re-diagnosed as a relapsed aGCT.
The analysis of two cases of aGCT plasma suggests that the pathognomonic aGCT associated FOXL2 mutation is present in recurrent disease. We also show that the presence of a ctDNA FOXL2 mutation confirms the differential diagnosis of recurrent disease. This is the first proof of principle that plasma DNA may be a non-invasive method to detect recurrent aGCT. Plasma samples from a large prospective cohort with primary or recurrent aGCT will be analyzed to test the sensitive of FOXL2 ctDNA to predict tumor burden. These studies will be imperative to determine the utilization of the plasma FOXL2 ctDNA mutation in routine diagnosis.
Citation Format: Melissa K. McConechy, Anniina Farkkila, Winnie Yang, Noora Andersson, Ying Ng, Leila Unkila-Kallio, Jessica N. McAlpine, Blake Gilks, Mikko Anttonen, David G. Huntsman. Circulating tumor DNA: FOXL2 402C-G mutation can be identified in plasma from adult granulosa cell tumor patients with recurrent disease. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 5610. doi:10.1158/1538-7445.AM2014-5610
Collapse
Affiliation(s)
| | - Anniina Farkkila
- 2Helsinki University Central Hospital (HUCH) and University of Helsinki, Helsinki, Finland
| | - Winnie Yang
- 3BC Cancer Agency, Vancouver, British Columbia, Canada
| | - Noora Andersson
- 2Helsinki University Central Hospital (HUCH) and University of Helsinki, Helsinki, Finland
| | - Ying Ng
- 3BC Cancer Agency, Vancouver, British Columbia, Canada
| | - Leila Unkila-Kallio
- 2Helsinki University Central Hospital (HUCH) and University of Helsinki, Helsinki, Finland
| | | | - Blake Gilks
- 1University of British Columbia, Vancouver, British Columbia, Canada
| | - Mikko Anttonen
- 2Helsinki University Central Hospital (HUCH) and University of Helsinki, Helsinki, Finland
| | - David G. Huntsman
- 1University of British Columbia, Vancouver, British Columbia, Canada
| |
Collapse
|